Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma

Eur J Cancer. 2018 Apr:93:147-149. doi: 10.1016/j.ejca.2018.01.062. Epub 2018 Feb 12.
No abstract available

Publication types

  • Letter
  • Multicenter Study

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Follow-Up Studies
  • Humans
  • Ipilimumab / administration & dosage
  • Melanoma / drug therapy*
  • Melanoma / pathology
  • Nivolumab / administration & dosage
  • Prognosis
  • Retrospective Studies
  • Survival Rate

Substances

  • Ipilimumab
  • Nivolumab